Eledon 10-Q: $69.7M Cash and Going-Concern Doubt Ahead of Phase 3 LEGACY
ELDN sits 79% above its 52-week low of $1.35.
Summary
Eledon's Q3 10-Q shows a $3.9M net loss propped up by a $17.0M non-cash warrant gain, $69.7M in cash, and an explicit going-concern warning that funding runs short within twelve months — before the Phase 3 LEGACY trial can start.
Key Events · Earnings and Guidance · ELDN
-
Q3 Loss Masked by Warrant Gain
Net loss was $3.9M ($0.03/share) versus $17.5M ($0.21) a year ago, but only because of a $17.0M non-cash gain from the change in fair value of warrant liabilities; excluding it, the loss was $21.0M.
-
Cash Falls to $69.7M
Cash, cash equivalents and short-term investments totaled $69.7M at September 30, 2026, down from $133.3M at December 31, 2025, with nine-month operating cash burn of $64.3M.
-
Going-Concern Doubt Disclosed
Management concluded existing resources will not fund planned operations for the next twelve months, including the Phase 3 kidney trial, and that financing plans do not alleviate substantial doubt.
-
Manufacturing Spend Jumps
Q3 R&D rose to $17.8M from $15.0M, driven by a $5.1M increase in manufacturing costs for clinical supply ahead of Phase 3 and the planned islet cell trial.
Analysis · ELDN · Life Sciences
A $17.0M non-cash warrant gain flatters the quarter's headline $3.9M net loss; excluding it, the operating loss was $21.0M, up from $17.5M a year ago as manufacturing spend for Phase 3 supply jumped. More important, the 10-Q states plainly that cash of $69.7M — down from $133.3M at year-end — will not fund operations for the next twelve months, and that management's financing plans do not alleviate substantial doubt about going concern. A capital raise is therefore a precondition for starting the ~600-patient Phase 3 LEGACY kidney trial in Q4 2026, making dilution risk the dominant variable for shareholders.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELDN was trading at $2.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.2M. The 52-week trading range was $1.35 to $4.49. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.